26.06.2018
Dermapharm Holding SE DE000A2GS5D8
DGAP-News: Dermapharm Holding SE: First Annual General Meeting after successful IPO
DGAP-News: Dermapharm Holding SE / Key word(s): AGM/EGM
Dermapharm Holding SE: First Annual General Meeting after successful IPO
26.06.2018 / 15:42
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Dermapharm Holding SE: First Annual General Meeting after successful IPO
Grünwald, June 26, 2018 - Dermapharm Holding SE (WKN A2GS5D, ISIN
DE000A2GS5D8), a leading producer of patent-free branded pharmaceuticals for
selected therapeutic areas in Germany with a growing international presence,
successfully held its first Annual General Meeting since its IPO this spring
at the Westin Grand Hotel in Munich on Tuesday. The presence of the
represented share capital was 87.76%. All items on the agenda were approved.
At the Annual General Meeting, the Management Board gave a detailed report
on the operative and strategic development of Dermapharm Holding SE in
fiscal year 2017 as well as the first quarter of 2018. Dermapharm has been
able to continue its success story of past years, reporting significant
revenue and earnings growth.
The year 2017 was shaped by preparations for the successful IPO on the Prime
Standard of the Frankfurt Stock Exchange in February 2018 and the
acquisition of several companies to expand and optimize its product
portfolio. Two very promising medical devices were also acquired in bite
away(R) and Herpotherm(R), which will be particularly active in
international marketing in the future. Group revenue in 2017 increased
significantly by 5.1% to EUR 467.1 million (2016: EUR 444.5 million).
Earnings before interest, taxes, depreciation and amortization (EBITDA),
adjusted for one-time costs of EUR 2.7 million in connection with IPO
preparations, improved by 9.9% to EUR 112.9 million (2016: EUR 102.7
million), corresponding to an adjusted EBITDA margin of 24.2%.
The first quarter of 2018 was characterized by the successful integration of
the acquired pharmaceutical manufacturer Bio-Diät-Berlin, Trommsdorff and
Strathmann and preparations for the internationalization of business
activities. The portfolio was expanded to include over-the-counter top
sellers such as Keltican(R) forte, Tromcardin(R) complex, Ebenol(R) and
China Öl(R). Highly promising prescription products for the core therapy
areas were also acquired. In addition, the foundation of mibe pharma Italia
Srl in Bolzano represented an important step in expanding the company's
international presence and opening up the promising Italian market for
Dermapharm products. Dermapharm increased its revenues in the first quarter
of 2018 by 16.4% to EUR 137.5 million (previous year's quarter: EUR 118.1
million). EBITDA adjusted for one-off costs of EUR 0.7 million in connection
with IPO preparations was significantly higher than in the same quarter of
the previous year at EUR 36.2 million (EUR 28.9 million). The adjusted
EBITDA margin was 26.3%.
In view of the Group's ongoing development through the three-pillar strategy
of in-house product development, internationalization and targeted M&A
activities, the Management Board expects to be able to continue achieving
profitable growth in the future. Assuming unchanged conditions and in light
of the positive business development in the first quarter of 2018, the
Management Board reconfirmed its full-year forecast for 2018 of revenue
growth of 20 to 25% and an improvement in EBITDA of 22 to 27% over fiscal
year 2017.
The actions of the Management Board and Supervisory Board were ratified by a
large majority at the Annual General Meeting for fiscal year 2017. Warth &
Klein Grant Thornton AG Wirtschaftsprüfungsgesellschaft, Düsseldorf, was
appointed as auditor for fiscal year 2018.
The detailed voting results on the respective agenda items will be published
soon online at www.ir.dermapharm.de.
Company profile:
Dermapharm - Pharmaceutical Excellence "Made in Germany"
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals
for selected markets in Germany. Founded in 1991, the company is based in
Grünwald near Munich and has its main manufacturing facility in Brehna near
Leipzig. The company's integrated business model comprises in-house
development, in-house production and distribution of pharmaceuticals and
other healthcare products for specifically targeted markets by a medical and
pharmaceutical sales force. Dermapharm holds approximately 900 marketing
authorizations (Arzneimittelzulassungen) for more than 200 active
pharmaceutical ingredients, which are reflected in a broad assortment of
products. This assortment makes the company unique. In addition to Germany,
the company's core markets also include Austria and Switzerland. The company
plans to further expand its international presence. Dermapharm's business
model also includes a parallel import business, which operates under the
"axicorp" brand. Based on revenues, Dermapharm was among the top four
parallel import companies in Germany in 2017.
With a consistent development strategy and numerous successful product and
company acquisitions over the past 25 years, Dermapharm has continuously
optimized its business and provided external growth impulses in addition to
organic growth. Dermapharm intends to continue this profitable growth course
in the future. The company is focusing on three strategic growth drivers:
in-house development of new products, increase of its international
footprint and further acquisitions. These include the acquisition of the
pharmaceuticals manufacturer and distributor Trommsdorff in January 2018,
whose portfolio includes the well-known brands Keltican(R) forte and
Tromcardin(R) complex.
Contact
cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
E-mail: [email protected]
---------------------------------------------------------------------------
26.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Stuttgart,
Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
698735 26.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Dermapharm Holding SE ISIN: DE000A2GS5D8 können Sie bei EQS abrufen
Gesundheit , A2GS5D , DMP , XETR:DMP